While many are familiar with weight-loss medication as an injectable daily treatment, a new form of the effective GLP-1 agonist drug could be set to arrive in the UK as early as next year. The manufacturer Eli Lilly, which produces Mounjaro – the injectable treatment that has become a highly sought-after medication in the UK, leading to price hikes and shortages – is currently in the late stages of trialling weight-loss medication in pill form. It's thought that the new form of medication, Orforglipron, would be extremely appealing to those who are already taking the drug to lose weight but find the idea of injectables off-putting. It'll also mean the medication is more accessible to underdeveloped countries.

According to The Times , the pharmaceutical company aren't far from gett

See Full Page